8-K
Catheter Precision, Inc. (VTAK)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
______________________________
FORM 8-K
______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 15, 2024
______________________________
| Catheter Precision, Inc. |
|---|
| (Exact name of registrant as specified in its charter) |
______________________________
| Delaware | 001-38677 | 38-3661826 |
|---|---|---|
| (State or other jurisdiction<br><br>of incorporation) | (Commission<br><br>File Number) | (IRS Employer<br><br>Identification No.) |
| 1670 Highway 160 West<br><br>Suite 205<br><br>Fort Mill, SC 29708<br><br>(Address of principal executive offices, including zip code) | ||
| --- |
(973) 691-2000
(Registrant’s telephone number, including area code)
NA
(Former name or former address, if changed since last report.)
______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.0001 per share | VTAK | NYSE American |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 15, 2024, John P. Francis informed the Board of Directors of Catheter Precision, Inc. (the “Company”) that he would not stand for reelection to the Board of Directors of the Company at the Company’s 2024 Annual Meeting of Stockholders scheduled for July 3, 2024. Mr. Francis’ term as a director will expire at the Annual Meeting. There is no disagreement between Mr. Francis and the Company with respect to any matter relating to the Company’s operations, policies or practices.
| 2 |
|---|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CATHETER PRECISION, INC. | ||
|---|---|---|
| Date: May 21, 2024 | By: | /s/ Margrit Thomassen |
| Margrit Thomassen<br><br>Interim Chief Financial Officer | ||
| 3 | ||
| --- |